Skip Navigation Links
28 June 2018

Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

28 June 2018 (Oxford, UK) - Oxford Cannabinoid Technologies (“OCT”), a biotechnology firm researching the potential of cannabinoid-based medications, announces today it has closed a Series A funding round. Investment was secured from Casa Verde Capital, Imperial Brands Ventures Ltd, and other Family Offices and Institutions.

The capital raised will be used to establish a strategic research partnership and laboratory in Europe. This will support OCT’s research into the mechanisms of cannabinoids in order to develop treatments that improve the quality of life for millions of patients around the world. Institutional involvement in OCT adds further impetus and credibility to the fast growing medical cannabis market.

OCT is establishing an Advisory Board of prominent scientists and policy makers from around the world. OCT today confirms that Baroness Meacher, the Chair of the All Party Parliamentary Group for Drug Policy Reform, has agreed to serve on its Advisory Board. Baroness Meacher said: “I’m thrilled that OCT has secured more funding and its much needed research is now under way. It is fantastic to see that Britain remains a world leader in pioneering medical research.” Both Sir Patrick Stewart and Baroness Meacher will be joining OCT in an unpaid capacity. Further appointments will be announced over the coming weeks.

Although there have been few clinical trials, cannabis has demonstrated efficacy in treating a multitude of conditions. However, more data is needed to uncover its full medicinal benefits. Beginning in early 2018, OCT has identified and prioritised several cannabinoid research proposals based on their clinical potential. With indications ranging from pain and inflammation to cancer and neurological disorders, OCT has commissioned research in many critical areas.  

“The therapeutic benefits of cannabis are vast, and OCT is the perfect partner to explore this within the growing biotech and pharmaceutical spaces,” said Karan Wadhera, the Managing Partner at Casa Verde Capital, the leading venture capital firm in the cannabis industry. “We’re inspired by OCT’s work and are excited to help fund research that could change countless lives.”

Kingsley Capital Partners (“KCP”) remains the largest shareholder in the business. Managing Partner of KCP and Chairman of OCT, Neil Mahapatra, said: “At a time when medical cannabis markets are opening across the world, it is still surprising how little focus appears to be dedicated to understanding the underlying molecular actions of cannabinoids. We want to help fill this knowledge gap, ultimately developing medical products that could help a large number of people.”

Matthew Phillips, Chief Development Officer, Imperial Brands PLC said: “We are pleased to be partnering with OCT. Cannabinoid products have significant potential and our investment enables Imperial to support OCT’s important research while building a deeper understanding of the medical cannabis market.”

In addition to the latest round of funding, OCT announces a new, highly experienced and diverse global management team:

  • Dr John Lucas (Chief Commercial Officer): a pharmaceutical executive with over 20 years of experience, John previously held executive level management positions, including Chief Executive Officer (Cizzle Biotechnology), General Counsel (Silence Therapeutics) and Vice President, Intellectual Property (Ilika plc, Metabasis Therapeutics, and Transform Pharmaceuticals), with further experience at the National Cancer Institute and Boehringer Ingelheim Pharma. John has also run his own consulting business where he assisted clients with business and legal/patent matters in biotech-pharma. His experience includes deal-making, corporate and product strategy, operations, and law/patents. John has a wide range of subject matter experience including small molecule pharmaceuticals (including cannabinoids), RNA therapy, biologics, and diagnostics. John holds a law degree (JD) from George Washington University and a doctorate in molecular genetics from The Ohio State University. He also holds a Master’s degree in microbiology and an undergraduate degree in biology from Ohio University.
     
  • Dr Jutta Roth (Chief Scientific Officer): with over fifteen years’ experience, Dr Roth previously served as Head of Strategic Development for Barts and The London School of Medicine and as Director of Partnerships for the Centre for Population Genomic Medicine in London. A published academic researcher, Jutta holds a PhD in Genetics with Distinction and an MSc in Microbiology from the University of Salzburg, with later research fellowships at Yale University and the UK National Institute for Medical Research.
     
  • Gavin Sathianathan (Non-Executive Director) CEO of Forma Holdings, engaging businesses in legal medical cannabis markets worldwide.
     
  • Hee-Dong Kim (Non-Executive Director) Co-Founder and Managing Partner at Kingsley Capital Partners.


- Ends - 


Notes to Editors

 

About Oxford Cannabinoid Technologies
Oxford Cannabinoid Technologies was established in 2017 to harness the prospective medical benefits of cannabinoids with a view to creating life-changing therapeutic outcomes for sufferers of acute and chronic conditions around the world. OCT has previously funded cannabinoid research projects at UK universities, and will fund additional cannabinoid projects at other academic institutions around the world.
 

About Kingsley Capital Partners
Kingsley Capital Partners (“KCP”) is a London-based investment firm that invests in private equity in the UK and emerging markets. Beyond its private equity activities, KCP has established and incubated a number of businesses on its balance sheet that operate in the legalised cannabis market, including Oxford Cannabinoid Technologies.

Neil Mahapatra, one of KCP’s Managing Partners, is a former President of the Oxford Union and graduated with a BA in Biological Sciences at Oxford. He is passionate about discovering whether and how medical cannabis can alleviate the suffering of people facing acute and chronic conditions, as a consequence of the death of his late mother from cancer. The experience led him to read about the medical potential of cannabinoids and ultimately conceive of OCT.
 

About Casa Verde Capital
Casa Verde Capital (“CVC”) is the leading venture capital firm focusing exclusively on the cannabis industry. As both the domestic and international cannabis markets continue to evolve and mature, CVC maintains a view that the cannabis industry will be among the most compelling investment themes of the next few decades. Primarily aimed at the ancillary cannabis ecosystem, which is commonly referred to as "not touching the plant," CVC invests in the legal, scalable "picks and shovels" that support the expanding industry.
 

About Imperial Brands Ventures Ltd
Imperial Brands Ventures Ltd is a subsidiary of Imperial Brands PLC, a dynamic fast moving consumer goods company borne out of a strong tobacco heritage. Imperial has evolved to embrace changing market dynamics and is increasingly focusing attention on developing and expanding its portfolio of Next Generation Products.
 

Media contacts

Fraser Schurer-Lewis

Acuitas Communications

T: +44 (0)7961 027 281/+44 (0)20 3687 0868

E: fraser.schurer-lewis@acuitascomms.com
 

Twitter: @OxCanTech

Facebook: @OxCanTech

LinkedIn: Oxford Cannabinoid Technologies

 

Simon Nayyar

Acuitas Communications

T: +44 (0)7799-767676/+44 (0)20 3687 0869

E: simon.nayyar@acuitascomms.com

Website: oxcantech.com

 

 

Related News articles

  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview
  • StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

    06 October 2022 StockBox
  • StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

    05 October 2022 StockBox
  • StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

    05 October 2022 StockBox
  • Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

    22 August 2022 StockBox
  • Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

    26 July 2022
  • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

    20 June 2022 Conference
  • OCT Investor Update 30 May 2022 - Q&A Questions

    30 May 2022 Investor Questions
  • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

    18 May 2022 Podcast
  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update
  • Data from pre-clinical study show positive results

    08 March 2022 Research Update
  • Requisition of General Meeting - Update

    04 March 2022 General Meeting
  • Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

    24 February 2022
  • Requisition of General Meeting

    18 February 2022 General Meeting
  • Notice of Analyst and Investment Presentation - How to Register

    17 February 2022 Presentations
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    18 November 2021 StemTech
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    17 November 2021 R&D Support
  • Posting of Annual Report, Notice of AGM and Form of Proxy

    27 October 2021 Annual Report, Notice of AGM and Form of Proxy
  • OCT Results and Company Update

    18 October 2021 Results and Company Update
  • Final Results and Notice of Annual General Meeting 13th October 2021

    13 October 2021 RNS
  • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

    12 October 2021 Trigeminal Neuralgia Interview
  • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

    11 October 2021 Program 2 Announcement
  • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

    30 September 2021 Pharmafocus Article
  • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

    28 September 2021 Podcast
  • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

    22 September 2021 Canopy Growth
  • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

    02 September 2021 US Market
  • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

    06 July 2021 Partnership
  • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    24 June 2021 iCDP Speaker
  • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    22 June 2021 Meet the Team Interview Series
  • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

    04 June 2021 Live Presentation
  • OCT Forges Partnership with Voisin Consulting Life Sciences

    OCT Forges Partnership with Voisin Consulting Life Sciences

    01 June 2021 OCT Partnership
  • Oxford Cannabinoid Technologies Announces Changes to Executive Team

    11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
  • OCT Company Values: How We Pursue Our Mission and Vision

    OCT Company Values: How We Pursue Our Mission and Vision

    01 December 2020 OCT Company Values
  • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

    Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

    26 October 2020 Meet the Team Interview Series
  • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

    07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release
  • Cannabinoids in medicine part 4: Epilepsy

    30 March 2020 Open Access Government
  • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

    07 January 2020 Open Access Government
  • Cannabinoids in medicine Part 2: Pain

    11 October 2019 Open Access Government
  • Cannabinoids in medicine Part 1: Cancer

    22 August 2019 Open Access Government
  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

    28 June 2018 OCT Press Release
  • Embracing the medical potential of cannabinoids

    01 June 2017 The Medicine Maker
  • Smashing the stigma with science

    01 June 2017 The Medicine Maker
  • Oxford University launches £10m research project into medical marijuana

    16 March 2017 Evening Standard
  • Oxford University launches £10m marijuana research programme

    16 March 2017 BBC
  • Oxford University to launch multimillion-dollar medical marijuana research program

    16 March 2017 CNBC
  • Oxford University to launch study on medical benefits of marijuana

    16 March 2017 The Telegraph
  • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

    15 March 2017 OCT Press Release